Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives

Head and Neck Cancer

A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies

Cancer Treat Rev

Jiménez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O'Leary B, Braña I, Harrington KJ

doi: 10.1016/j.ctrv.2024.102772

Head and Neck Cancer

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

Lancet Oncol

Lim AM, Le Tourneau C, Hurt C, Laskar SG, Steuer CE, Chow VLY, Szturz P, Henson C, Day AT, Bates JE, Lazarakis S, McDowell L, Mehanna H, Yom SS, HNCIG

doi: 10.1016/S1470-2045(24)00068-8

Head and Neck Cancer

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

J Clin Oncol

Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr

doi: 10.1200/JCO.23.02625

Head and Neck Cancer

Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis

Clin Cancer Res

Saba NF, Chaudhary R, Kirtane K, Marra A, Ekpenyong A, McCook-Veal A, Schmitt NC, Gross JH, Patel MR, Remick J, Bates JE, McDonald MW, Rudra SF, Stokes WA, Biernacki M, Song X, Slebos RJC, Liu Y, Steuer CE, Shin DM, Teng Y, Chung CH

doi: 10.1158/1078-0432.CCR-24-1202

Head and Neck Cancer

Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma

J Cancer Res Clin Oncol

Huwyler F, Giger R, Bill R, Rauch D, Haefliger S

doi: 10.1007/s00432-024-06044-2

Genitourinary Cancer

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cancer Treat Rev

Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H

doi: 10.1016/j.ctrv.2024.102787

Head and Neck Cancer

Chronotherapy in head and neck cancer: A systematic review and meta-analysis

Int J Cancer

Abusamak M, Abu-Samak AA, Cai W, Al-Waeli H, Al-Hamed FS, Al-Tamimi M, Juweid M, Chaurasia A, Nicolau B, Tamimi F

doi: 10.1002/ijc.35234

Further Publications

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Clin Cancer Res

Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, Rejeski K

doi: 10.1158/1078-0432.CCR-24-1798

Gastrointestinal Cancer

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline

J Clin Oncol

Morris VK, Kennedy EB, Amin MA, Aranha O, Benson AB 3rd, Dorth JA, Horowitz DP, Kennecke HF, Kim S, Kreppel L, Mettu NB, Rajdev L, Riechelmann R, Sio TT, Eng C

doi: 10.1200/JCO-24-02120

Related content

A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies

Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis

Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Chronotherapy in head and neck cancer: A systematic review and meta-analysis

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline